A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Phase 1 Completed 50 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.

Timeline

Start: 2021-03-09
Primary completion: 2023-04-26
Completion: 2023-04-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Centanafadine	Small molecule	—	Oral

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Summary

Timeline

Drugs

Indications